Trial Profile
Effects of AMPA [alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid] receptor blockade on human cortical excitability - a pilot study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2008
Price :
$35
*
At a glance
- Drugs Talampanel (Primary)
- Indications Amyotrophic lateral sclerosis; Epilepsy
- Focus Pharmacodynamics
- 21 Mar 2008 New trial record.